CMPS

COMPASS Pathways

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 0

consensus rating "Strong Buy"

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About CMPS

Compass Pathways Plc

A UK developer of psilocybin therapy for the treatment of resistant depression

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

09/18/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

166

Fiscal Year Ends

12-31

Website

www.compasspathways.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

33 Broadwick Street, London W1F 0DQ, United Kingdom

Business

Introduction

COMPASS Pathways plc is incorporated in England and Wales. COMPASS Pathways plc is a mental health care company that promotes patient access to evidence-based mental health care innovations. The company is motivated by the need to find better ways to help and empower people with mental health challenges who are not helped by existing therapies, and is pioneering a new psilocybin treatment model that combines psilocybin with psychological support.

Company Financials

EPS

CMPS has released its 2024 Q4 earnings. EPS was reported at -0.63, versus the expected -0.64, beating expectations. The chart below visualizes how CMPS has performed over recent quarters, highlighting trends in earnings surprises.